

# Evaluating COVID-19 reporting data in the context of testing strategies across 31 LMICs

Mollie M. Van Gordon, Ph.D.<sup>1,\*</sup>, Kevin A. McCarthy, Ph.D.<sup>1</sup>, Joshua L. Proctor, Ph.D.<sup>1</sup>, Brittany L. Hagedorn, MBA<sup>1</sup>

---

## Abstract

### *0.1. Background*

COVID-19 case counts are the predominant measure used to track epidemiological dynamics and inform policy decision-making. Case counts, however, are influenced by testing rates and strategies, which have varied over time and space. A method to consistently interpret COVID-19 case counts in the context of other surveillance data is needed, especially for data-limited settings in low- and middle-income countries (LMICs).

### *0.2. Methods*

We leverage statistical analyses to detect changes in COVID-19 surveillance data. We apply the pruned exact linear time change detection method for COVID-19 case counts, number of tests, and test positivity rate over time. With this information, we categorize change points as likely driven by epidemiological dynamics or non-epidemiological influences such as noise.

---

\*Corresponding author: [mvangordon@idmod.org](mailto:mvangordon@idmod.org); +1 (425) 526-3104

<sup>1</sup>Institute for Disease Modeling at the Bill & Melinda Gates Foundation, Seattle, WA, USA

### *0.3. Findings*

Higher rates of epidemiological change detection are more associated with open testing policies than with higher testing rates. The non-pharmaceutical intervention most correlated with epidemiological change is workplace closing. LMICs have the testing capacity to measure prevalence with precision if they use randomized testing. Rwanda stands out as a country with an efficient COVID-19 surveillance system. Sub-national data reveal heterogeneity in epidemiological dynamics and surveillance.

### *0.4. Interpretation*

Relying solely on case counts to interpret pandemic dynamics has important limitations. Normalizing counts by testing rate mitigates some of these limitations, and open testing policy is key to efficient surveillance. Our findings can be leveraged by public health officials to strengthen COVID-19 surveillance and support programmatic decision-making.

### *0.5. Funding*

This publication is based on models and data analysis performed by the Institute for Disease Modeling at the Bill & Melinda Gates Foundation.

---

## Research in Context

### *Evidence before this study*

We searched for articles on the current practices, challenges, and proposals for COVID-19 surveillance in LMICs. We used Google Scholar with search terms including “COVID surveillance.” Existing studies were found to be qualitative, anecdotal, or highly location-specific.

### *Added value of this study*

We developed a quantitative method that makes use of limited information available from LMICs. Our approach improves interpretation of epidemiological data and enables evaluation of COVID-19 surveillance dynamics across countries.

### *Implications of all the available evidence*

Our results demonstrate the importance of open testing for strong surveillance systems, bolstering existing anecdotal evidence. We show strong alignment across LMICs between workplace restrictions and epidemiological changes. We demonstrate the importance of considering sub-national heterogeneity of epidemiological dynamics and surveillance.

1

## 2 1. Introduction

3 The virus known as SARS-CoV-2 was first identified in Wuhan, China in De-  
4 cember 2019. Since then, countries have scrambled to monitor the severity  
5 and trajectory of the COVID-19 outbreak and to control its progression using  
6 non-pharmaceutical interventions (NPIs). Disease surveillance has mostly  
7 relied on case counts to inform public health policies.<sup>1</sup> There has not, how-  
8 ever, been a robust evaluation of case counts as a metric for epidemiological  
9 dynamics, nor the varied surveillance approaches used to track disease tra-  
10 jectories.

11 Case-based surveillance systems have known weaknesses, including the strong  
12 influence of testing rates, which vary widely across space and time.<sup>2</sup> Case

13 counts can be inconsistently measured, testing capacity limited, and eligibil-  
14 ity policies variable. It is critical to understand the limitations of available  
15 data and to identify metrics that are robust to these challenges, particularly  
16 for low- and middle-income countries (LMICs).

17 There is general recognition that surveillance system performance can be  
18 a challenge in LMICs, and that understanding disease surveillance is key  
19 to system improvement and production of representative data.<sup>3</sup> Existing ef-  
20 forts to evaluate LMIC surveillance systems, however, are largely qualitative,  
21 country-specific, or based on commentary.<sup>4-6</sup> Further, most national-level  
22 studies of NPI impacts focus on high-income countries,<sup>7-11</sup> but there is evi-  
23 dence that these insights cannot be readily generalized to LMIC settings.<sup>12,2</sup>  
24 This leaves an important knowledge gap in understanding how to evaluate  
25 and interpret COVID-19 epidemiological data from LMICs.

26 To address the gap in systematic interpretation and evaluation methods, we  
27 leverage statistical analysis techniques to detect changes in underlying prop-  
28 erties of COVID-19 time series surveillance data across 31 LMICs. With this  
29 information, we categorize detected change points as likely driven by epi-  
30 demiological changes or non-epidemiological influences such as noise. This  
31 provides a quantitative and automated approach to analyzing epidemiolog-  
32 ical surveillance data. We make use of imperfect information despite data  
33 weaknesses, deriving insights from information available in LMICs that may  
34 otherwise be overlooked. The approach is fast and highly portable, well  
35 suited to looking across countries, and has minimal data requirements.

36 In this article, we first present the methods for our analysis, including the  
37 statistical model, change point categorization, and evaluation of epidemio-  
38 logical change co-occurrence with NPIs. We follow with validation of our  
39 method, the usefulness of open testing, comparisons of country surveillance  
40 characteristics, and consideration of sub-national dynamics. Finally, we elab-  
41 orate on the significance of our results, broader conclusions, and relevance  
42 for public health applications.

43 **2. Methods**

44 The methods are outlined in Figure 1 for two example countries: South Africa  
 45 and Bangladesh. Details about each step are presented in the following sub-  
 46 sections.




Figure 1: Methods Overview. Time series for cases (orange), tests (blue) and positivity (green) for case study countries South Africa and Bangladesh. Vertical lines indicate detected change points on each series. National changes in testing policy are shown as blue bars; see Section 2.1 for policy descriptions. Positivity change points are overlaid with case and test changes. Change points from the three time series are grouped in time; shading on positivity changes indicates grouping tolerance. Category labels for change point groups are shown above positivity and described in Figure 2. Black arrows indicate NPI changes; arrow direction indicates increase or decrease in stringency. For categories D and E, Y(es) and N(o) in boxes below positivity indicate whether there is a co-occurring NPI change inverse to the change in slope of positivity.

## 47 *2.1. Data*

48 We use national-level case and testing data as well as records on national  
49 policies for testing and NPIs.<sup>13,14</sup> We calculate test positivity by dividing  
50 case rate by test rate. Testing policy is indicated by ordinal values: zero  
51 indicates no testing policy; one indicates testing of those with symptoms  
52 who meet specific criteria (e.g. known contact with a positive individual);  
53 two indicates testing of any symptomatic individuals; three indicates open  
54 public testing. For South Africa, we also use provincial-level data on COVID-  
55 19-confirmed deaths, cases and testing rates, and excess mortality.<sup>15–18</sup>

56 We selected countries for analysis based on three conditions: available case  
57 data, available testing data, and human development index (HDI) score. Of  
58 those with data, we included the countries in the lowest third of HDI score,  
59 all of which are considered low- or middle-income in 2020-2021 by the World  
60 Bank. All data used in this research are public. Further details on data and  
61 definitions found in Appendix A.1.

## 62 *2.2. Change point detection*

### 63 *2.2.1. Pruned Exact Linear Time (PELT) change detection*

64 Change point detection is a set of approaches for identifying points in time  
65 where the statistical properties of a time series change.<sup>19</sup> We apply change  
66 point detection to epidemiological time series (cases, tests, and positivity)  
67 and national policy time series; details in Appendix A.2. Without a priori  
68 knowledge of the appropriate number of changes, the PELT algorithm must  
69 be assigned a penalty for the number of changes to identify. In the absence  
70 of an established method for this parameterization when working across time  
71 series, we developed a novel systematic approach for penalty selection which  
72 enables comparison among time series and countries; described in Appendix  
73 A.3.

### 74 *2.2.2. Method validation*

75 We applied PELT to synthetic data generated by the stochastic agent-based  
76 Epidemiological Modeling software (EMOD),<sup>20</sup> verifying PELT as a robust

77 method for change detection in epidemiological time series. The EMOD  
78 model used for our validation analysis is parameterized to represent transmis-  
79 sion characteristics in Ethiopia. The model scenario inputs include step-wise  
80 increases in social distancing stringency, along with temporary decreases in  
81 stringency representing immunization campaigns. The model outputs a sim-  
82 ulated time series of cases per thousand people. The change point detection  
83 methods described above are applied to the seven-day mean of the case rate  
84 time series to align with the data smoothing used with our empirical time  
85 series.

### 86 *2.3. Change type categorization*

87 Change detection identifies changes that may be related to data quality,  
88 stochasticity, and testing dynamics, in addition to epidemiological changes.  
89 We classify the likely cause of changes identified by the PELT algorithm based  
90 on which changes co-occur. This categorization simplifies the interpretation  
91 of epidemiological surveillance, separates signal from noise, and enables broad  
92 comparison across countries and testing dynamics.

93 We combine detected change points across cases, tests, and positivity time  
94 series to create change point groups. The tolerance for temporal association  
95 is set at  $\pm$  seven days to account for seven-day smoothing and weekly data  
96 reporting practices. These change groups are then categorized as shown in  
97 Figure 2, with details of the interpretation described in Appendix B. To  
98 capture all changes that may be epidemiological, we include both categories  
99 D and E as epidemiological change in our analysis. We note that these cate-  
100 gories are heuristically defined, however they are informed both by validation  
101 using the EMOD simulations and a qualitative understanding of epidemio-  
102 logical surveillance dynamics.

Label	Constituent time series	Description	Origin
(A)	C / T / P	Single variable change	Data issues/noise
(B)	C + T	Cases and tests move together	Likely non-epi
(C)	T + P	Tests drive positivity change	Likely non-epi
(D)	C + P	Cases drive positivity change	Likely epi
(E)	C + T + P	Cases, tests, positivity change	Confounded

Figure 2: Summary of change group categories as determined by their constituent time series changes. Cases, tests, and positivity time series are indicated as orange, blue, and green, respectively. Details of the category interpretations are described in Appendix B.

#### 103 2.4. NPI alignment

104 Change points classified as epidemiological are then assessed for whether they  
 105 are associated with NPI changes. Timings of known NPIs are lagged by nine  
 106 days to account for virus incubation time and the delay from symptom onset  
 107 to test-seeking.<sup>21</sup> We consider a change point to be aligned with an NPI when  
 108 two conditions are met: 1) an epidemiological change co-occurs with an offset  
 109 NPI and 2) the change in NPI stringency is inverse to the concurrent change  
 110 in positivity slope. The second condition includes occasions when stringency  
 111 was increased and positivity decreased, as well as occasions when stringency  
 112 decreased and positivity increased.

### 113 3. Results

#### 114 3.1. Synthetic modeling validates Pruned Exact Linear Time (PELT) is a 115 robust method for change detection in epidemiological time series.

116 Before applying the PELT method to the surveillance data, we validate its  
 117 applicability for epidemiological systems. We apply PELT change detection  
 118 to data from the transmission model described in Section 2.2.2. PELT suc-  
 119 cessfully identifies step changes in NPI policies and slope changes in case  
 120 rate, Figure 3.



121 While detection of NPI changes is consistent across a range of PELT penal-  
122 ties, change point detection is sensitive to parameterization when applied to  
123 the case rate time series, Figure 3B. When implemented with a high penalty  
124 (i.e. fewer change points), the PELT algorithm successfully identifies changes  
125 corresponding to the large-scale social distancing policies and changes in the  
126 basic shape of the case curve. With this penalty, it does not detect the rela-  
127 tively transient effects of the immunization campaigns. When parameterized  
128 with a low penalty (i.e. more change points), the PELT algorithm identifies  
129 the immunization campaigns as well.




Figure 3: Synthetic model time series; detected change points shown as vertical dotted lines. A) Imposed policy inputs to model: social distancing (purple) and immunization campaigns (brown). Short-term immunization campaigns represented by a switch in the immunization time series from one to zero. B) Model output: case rates over time. Upper plot shows detected change points using a high penalty, thereby promoting sparse change point detection. Lower plot shows detected change points using a low sparsity penalty.

130 *3.2. Testing rates and policies impact how surveillance measures should be*  
131 *interpreted.*

132 We illustrate the relevance of testing rates and the influence of testing policy  
133 using time series for Bangladesh in the context of local events (Figure 1).  
134 Case rates peaked in early July, an apparent epidemiological turning point if  
135 case rates were considered alone. Simultaneously, however, there was a new

136 policy implemented to charge for testing and thus a decline in testing rate.<sup>22</sup>  
137 This resulted in no change in positivity and contradicts the interpretation of  
138 the case reduction as a declining outbreak. Similarly, the dip in case rate in  
139 early August was accompanied by a dip in testing rate during the Eid al-Fitr  
140 holiday; again there is no change in positivity.

141 While this recommends positivity as a surveillance metric instead of case  
142 counts alone, further consideration of testing policy complicates the picture.  
143 Test eligibility in Bangladesh is based on symptoms rather than open testing,  
144 meaning that positivity is influenced by the prevalence of both COVID-19  
145 and other respiratory illnesses. This limits the potential for positivity to de-  
146 tect epidemiological changes, and indeed, the positivity curve for Bangladesh  
147 is largely flat. An elaboration of COVID-19 surveillance considerations ap-  
148 pears in Appendix C.

149 *3.3. Epidemiological change detection is more influenced by testing policy*  
150 *than by testing rate.*

151 For all 31 LMICs in our dataset, we apply PELT change detection and change  
152 point categorization. We quantify surveillance system efficiency as the per-  
153 centage of all detected change points classified as epidemiological, i.e. epi-  
154 demiological change detection rate. We compare linear fits of epidemiological  
155 change detection by testing rate and by testing policy (Figure 4). Results  
156 indicate that the ability to identify epidemiological changes has a stronger  
157 relationship with testing policy than with testing rate. Open testing is the  
158 only testing policy bin with a mean or median epidemiological change detec-  
159 tion rate as high as 50%, but with a wide range, indicating that open testing  
160 policy is necessary but not sufficient for quality surveillance (with outlier  
161 exceptions).




Figure 4: Percent of detected changes categorized as epidemiological for each country by testing rate (left) and binned by testing policy (right) at the time of change detection. Linear regression shown as dotted line on left. Box and whisker plots on right show quartiles, range, and median with means plotted as gray diamonds. Note that binned calculations cause the maximum epidemiological change detection rate to differ between the two plots.

162 Further, LMICs have the testing capacity to measure prevalence with pre-  
163 cision. Based on the 95th percentile of their daily testing rates, nearly all  
164 LMIC countries could measure down to 1% prevalence with a margin of er-  
165 ror no larger than  $\pm 1\%$  if testing were randomly sampled (Figure 5). Only  
166 three countries hover around the margin of error to prevalence ratio of one:  
167 Malawi, the Democratic Republic of Congo, and Togo. Note that true ran-  
168 dom sampling is difficult to achieve in any setting, but open testing policies  
169 can approximate random sampling more closely than symptomatic testing.




Figure 5: Margin of error for random sampling of 1% prevalence plotted by 95th percentile of national testing rate and population of each country in our dataset. See Appendix D for details on standard error calculations.

170 *3.4. Change detection rates and NPI alignment frequency vary across LMICs.*

171 Figure 6 shows frequencies of change category detection across countries.  
172 Rwanda is an outlier with high epidemiological detection accompanied by low  
173 non-epidemiological and noise detection rates. High rates of noise detection  
174 are generally associated with low rates of epidemiological change detection,  
175 whereas the relationship between noise detection and non-epidemiological  
176 change detection is not consistent.




Figure 6: Change type ratios by country. The sum of categories D and E (considered epidemiological changes) normalized by the total number of changes per country on the y-axis. Category B (non-epidemiological) change detection rate on x-axis. Category A (noise-related) change detection rate shown in color.

177 Figure 7A shows the wide variation of epidemiological change detection rates  
178 across LMIC countries, with Rwanda the highest and Ethiopia the lowest.  
179 The percentage of NPIs that are aligned with an epidemiological change is  
180 shown in Figure 7B, again led by Rwanda. Note that Rwanda performs well  
181 by these metrics regardless of change detection parameterization, Appendix  
182 A.4.




Figure 7: Epidemiological change detection rates (A) and NPI alignment rates (B) by country.

183 *3.5. Alignment with detected epidemiological changes varies by NPI type.*

184 The NPIs most frequently aligned with epidemiological changes are work-  
 185 place closures, public transport closures, and stay at home requirements.  
 186 The percentage of these NPIs that are aligned with epidemiological changes  
 187 are 15.1%, 14.3%, and 12.2%, respectively. Note that there are substantially  
 188 fewer total public transit NPIs than workplace closures and stay at home

189 requirements. Cancelling public events has the lowest frequency of epidemi-  
190 ological alignment at 6.12%, and also the fewest number of implementation  
191 incidences.




Figure 8: The percentage of each type of NPI aligned with an epidemiological change. Color indicates the total number of each type of NPI across all countries; error bars show standard error. NPIs include both easing and tightening of policy restrictions.

192 *3.6. National-level results obscure sub-national heterogeneity in epidemiolog-*  
193 *ical dynamics and surveillance.*

194 To investigate sub-national heterogeneity, we conduct the same analyses as  
195 above, but at the province level in South Africa. Figure 9A shows substantial  
196 variability in provinces both by NPI alignment rate and by epidemiological  
197 change detection rate. In line with results from national-level data, epi-  
198 demiological change detection rate is not correlated with mean testing rate.  
199 Because of reporting limitations, the NPIs here are national policies only.

200 We select three edge cases from the scatter plot in Figure 9A (Limpopo,

201 Northern Cape, and Western Cape) to compare time series of positivity,  
202 COVID-19-confirmed deaths, and total estimated excess mortality (Figure  
203 9B). The differences in the timing and trajectories of the time series illustrate  
204 strong sub-national variability in underlying epidemiological dynamics that  
205 are may be overlooked when time series are aggregated to the national level.

206 Variation among provinces in the difference in magnitude between excess  
207 mortality and COVID-19 deaths points to differences in their surveillance  
208 systems. Western Cape is the only province where the magnitude of excess  
209 deaths resembles that of COVID-19-confirmed deaths throughout the time  
210 series. In Northern Cape, the peak of excess deaths is roughly a factor of  
211 three higher than the COVID-19-confirmed deaths, suggesting substantial  
212 under-reporting.






Figure 9: A) South African provinces by aligned NPI fraction versus epidemiological detection rate with mean testing rate in color. B) Time series from three example provinces. Positivity shown in green on left y-axis. Deaths shown on the right y-axis: excess mortality in black; COVID-19-confirmed deaths in brown.

## 213 4. Discussion

214 We have demonstrated a standardized and quantitative approach to ana-  
215 lyzing epidemiological surveillance time series that can be automated for  
216 improved interpretation and comparison between countries. We find that in-  
217 terpretation of epidemiological trajectories are more informative when cases  
218 are normalized by tests and highlight the disadvantages of symptomatic test-  
219 ing for outbreak tracking and public health purposes. These findings align  
220 with literature emphasizing the importance of positivity and test sampling  
221 strategies.<sup>23,24</sup> Our finding of a strong alignment of workplace closing with  
222 epidemiological changes is consistent with existing literature on global NPI  
223 impacts.<sup>12,25,26</sup> When we apply our analysis of change types to evaluate the  
224 efficiency of national surveillance systems, we find that Rwanda stands out as  
225 a country with a strong surveillance system, which is consistent with current  
226 qualitative evaluation.<sup>27</sup>

227 Our approach substantially broadens the scope of previous analyses of COVID-  
228 19 surveillance data in LMICs. We use statistical change detection methods  
229 on COVID-19 surveillance time series from 31 LMICs to differentiate epi-  
230 demiological changes from changes related to stochasticity, data quality and  
231 non-epidemiological dynamics. This maximizes the insights gained from lim-  
232 ited data, reduces erroneous interpretations of epidemiological time series,  
233 and enables quantitative comparisons of disease surveillance approaches. We  
234 use epidemiological change detection rate as a proxy for surveillance system  
235 efficiency, and show that epidemiological change detection is not as strongly  
236 associated with testing rate as with open testing policies. There is substan-  
237 tial variation in epidemiological and surveillance dynamics across countries  
238 and in our sub-national analysis.

239 There are limitations in our analysis related to the data themselves as well  
240 as our methods. Simultaneously, these data challenges are precisely the mo-  
241 tivation for developing our methods: maximizing information with limited  
242 data. Our data are potentially biased by unmeasured factors such as fluctu-  
243 ations in testing capacity and undocumented population sampling strategies  
244 over time, delays and temporal uncertainty due to reporting systems, and  
245 incentives for case-finding. Defining co-occurrence when working with im-  
246 precise time series is a challenge, which we partially mitigate by considering  
247 uncertainty bounds when defining change groups. We emphasize, of course,

248 that co-occurrence does not establish causality. In PELT change detection,  
249 the changes detected are influenced by the choice of the sparsity parameter.  
250 In a sensitivity analysis of our novel parameterization approach, however,  
251 we find that Rwanda remains the leader in surveillance system performance,  
252 regardless of the parameterization choice.

253 Results from this analysis highlight that surveillance data must be used care-  
254 fully to ensure proper programmatic responses. As a sufficient and less  
255 resource-intensive approximation of random sampling, open testing would  
256 enable better estimation of disease prevalence and examination of NPI im-  
257 pacts in geographies without reliable hospitalization data, death records, or  
258 seroprevalence surveys. NPIs without epidemiological changes may indicate  
259 inefficacy of policy, but may also indicate shortfalls of surveillance systems,  
260 which undermines policy makers' ability to make evidence-based decisions.  
261 Our methods could be further developed and applied not just to COVID-19  
262 but also to surveillance interpretation for other poorly measured diseases, en-  
263 abling more informed decision-making and targeted improvements in surveil-  
264 lance systems.

## 265 **5. Declarations**

### 266 *5.1. Declaration of interests*

267 The authors declare no conflicts of interest.

### 268 *5.2. Role of funding source*

269 This publication is based on models and data analysis performed by the  
270 Institute for Disease Modeling at the Bill & Melinda Gates Foundation. The  
271 funder had no influence on the analysis or conclusions presented here.

## 272 **Appendix A. Methods**

### 273 *Appendix A.1. Data and definitions*

274 The case rate is defined as the number of individuals confirmed positive  
275 for the SARS-CoV-2 virus per population, regardless of symptoms. The  
276 testing rate per population is defined as the number of people tested (i.e.  
277 excluding duplicate confirmatory tests) divided by the population, regardless  
278 of the test outcome. To address the dependence of case rate on testing rate,  
279 we normalize case counts by the number of tests conducted, creating the  
280 alternate metric of test positivity rate.

281 For the purposes of comparing between countries and over time, we define the  
282 ‘mean testing policy’ as the average over time of the ordinal value represent-  
283 ing the national testing policy. Thus, lower values represent more restricted  
284 testing over longer periods of time. Social distancing policies tracked in the  
285 dataset include the following: closing schools, closing workplaces, cancelling  
286 public events, restricting gathering sizes, closing public transport, stay at  
287 home requirements, restricting in-country mobility, and restricting interna-  
288 tional travel.

289 Weekly cases, testing, and death data are interpolated using a cubic spline.  
290 All daily cases, testing and death data are smoothed using a centered seven-  
291 day rolling average. Error bars on plots show standard error.

### 292 *Appendix A.2. PELT change detection*

293 The naive approach to generating an exact solution to time series segmenta-  
294 tion is to test all possible solutions. For an unknown number of changes, this  
295 also requires testing a sufficiently large set of possible number of changes.  
296 We use the Pruned Exact Linear Time (PELT) change detection method to  
297 address these computational tractability issues.

298 PELT minimizes the sum of costs from a criterion function across time series  
299 segments while balancing model complexity by implementing a linear penalty  
300 function and change point pruning. At each iteration of cost minimization for  
301 a potential set of change points, time points that cannot be a global minima

302 are removed from future consideration. The PELT method, developed with  
303 applications in genetics and finance in mind, is increasingly used for climate  
304 and epidemiological applications.<sup>28–30</sup>

305 To detect changes in slope of the epidemiological time series, we use the  
306 first derivative as input for the PELT algorithm. For detection of discrete  
307 step changes of policy time series, we feed the data directly into the change  
308 detection algorithm without taking a derivative. For all time series, we use  
309 the radial basis function kernel for the PELT detection algorithm.

### 310 *Appendix A.3. PELT parameterization*

311 To date, there is no established method for parameterizing the PELT change  
312 density penalty across time series when the number of changes is not known.  
313 One of the ways to choose penalty values across time series would be to unify  
314 the number of changes detected in each time series. This, however, imposes  
315 the assumption that all time series exhibit the same general change frequency  
316 and it is only the point in time of a change that is unknown, rather than the  
317 number of changes.

318 We present here a novel approach for systematic parameterization when iden-  
319 tifying an unknown number of changes in slope over many time series, as in  
320 our case with multiple epidemiological time series across countries. To ac-  
321 complish this, we first conduct change detection in a sweep over parameter  
322 space. The change points detected using a given value in parameter space  
323 slice the time series into segments, each of which is input into a linear re-  
324 gression. The standard error for each of those linear regressions is calculated  
325 and then averaged, weighted by segment length.

326 The mean standard error associated with each penalty value, when plotted  
327 over parameter space, is characterized by a series of plateaus that correspond  
328 to plateaus in the number of changes found with each penalty value, Figure  
329 A.10, top row. Descending through penalty values in the penalty parameter  
330 space, the lowest penalty associated with each plateau is selected to represent  
331 that plateau.

332 Each time series is thus associated with a sparse set of penalty values, ordered  
333 from largest penalty (low change point density) to smallest penalty (high

334 change point density). The penalty values are unique to each time series,  
335 but represent the same ordered progression of plateaus. To illustrate, change  
336 detection with different ranked penalties for South Africa and Bangladesh  
337 are shown in green in Figure A.10.

338 Penalty values for each unique time series can then be chosen based on their  
339 order in the ranked plateau list. This enables a principled approach to pa-  
340 rameterization that creates change density parity across time series, allowing  
341 for the likelihood that some time series are characterized by more changes  
342 than others. Among all time series and countries in our analysis, the min-  
343 imum number of plateaus detected is four. We therefore choose the fourth  
344 penalty value for all time series.




Figure A.10: Top row: change detection results over parameter space for the positivity time series of South Africa (left) and Bangladesh (right). For each penalty value, the associated number of changes is plotted in purple on the left y-axis and the mean standard error of linear regressions of the time series segments are plotted on the right y-axis. The parameter values selected to represent plateaus are shown as brown dotted vertical lines. Bottom row: positivity time series for South Africa (left) and Bangladesh (right) plotted with detected changes as vertical lines for each of the four penalty values selected to represent plateaus in the top row.

345 *Appendix A.4. Parameterization sensitivity analysis*

346 To evaluate the influence of penalty selection on our analysis results, we con-  
 347 duct a parameterization sensitivity analysis. We compare results of country

348 ranking by epidemiological change detection rate for different penalty plateau  
 349 selections. Skipping penalty rank one for which no changes may be detected  
 350 (see examples in Figure A.10), we find that regardless of which penalty rank  
 351 we use, Rwanda appears at the top of the list with the highest epidemiological  
 352 change detection rate.




Figure A.11: Countries ranked by epidemiological change detection rate, as in Figure 7, shown for different choices of penalty parameterization. Order top to bottom follows order of time series of Figure A.10, without rank one for which there are often no changes.



## 353 Appendix B. Change categorization

### 354 *Appendix B.1. Heuristic interpretation*

355 Detected change points across cases, testing, and positivity time series are  
356 combined into groups by temporal co-occurrence. These groups are then  
357 categorized by their constituent time series, Figure 2. Dynamical interpreta-  
358 tion of the constituent time series aids in the characterization of each change  
359 group category, as follows:

- 360 A) Single variable change: Because positivity is defined according to the  
361 arithmetic relationship,  $Positivity = Cases/Tests$ , a change in any one  
362 of the variables should be accompanied by a change in at least one of the  
363 other variables. A single change in only one of the variables indicates that  
364 the change arises from issues in the data or noise. These single variable  
365 changes often occur early in the time series, when the numbers of cases  
366 and tests are smaller, signal to noise ratios are lower, and confidence  
367 intervals are larger.
- 368 B) Cases and tests change: Tests and cases move up or down together.  
369 What might look like a significant change in cases is associated with a  
370 change in testing, likely not a change in epidemiology. Factors affecting  
371 testing include testing capacity, care-seeking behavior, and testing sam-  
372 pling policy. With this change category, the change in testing could be  
373 a change in capacity or care-seeking, but the lack of change in positiv-  
374 ity indicates testing is still sampling the same population the same way,  
375 without changes in epidemiology.
- 376 C) Tests and positivity change: Positivity change is driven by testing change,  
377 not a change in cases. An increase or decrease in testing does not impact  
378 absolute numbers of detected cases, which suggests a change in test sam-  
379 pling. Dynamics that would produce this pattern include, for example,  
380 adding population with lower prevalence in the case of open testing, or  
381 limiting testing to a higher-prevalence population in the case of symp-  
382 tomatic testing. It is also possible, however, that a change in testing  
383 sampling masks a simultaneous change in epidemiology. In this situa-  
384 tion, the change in testing would have to precisely offset the change in  
385 epidemiology to observe this category of change association. Category C  
386 is thus designated to likely indicate a non-epidemiological change.

- 387 D) Cases and positivity change: Positivity change is driven by a change in  
388 cases without a change in testing. This suggests a change in epidemiology,  
389 but the significance may be different under random vs. symptomatic test-  
390 ing. Under random testing, this type of change arises only with a change  
391 in SARS-CoV-2 epidemiology. Under symptomatic testing, the restric-  
392 tion of sampling to CLI means that a change in the epidemiology may  
393 be confounded by a change in CLI epidemiology. Note also that symp-  
394 tomatic testing captures changes only in symptomatic SARS-CoV-2 (i.e.  
395 cases of COVID-19). Another possible explanation for this combination  
396 of changes is a change in sampling without a change in the absolute num-  
397 ber of tests. This might occur, for example in a switch from symptomatic  
398 to open testing. For this reason, we categorize this change combination  
399 as likely instead of certainly epidemiological.
- 400 E) All three variables change: With a change in cases, tests, and positivity, it  
401 remains difficult to disentangle epidemiological from non-epidemiological  
402 factors. Category E can be considered a combination of categories C and  
403 D, and the testing and case changes may or may not be independent. To  
404 capture all changes that may be epidemiological, we consider categories  
405 D and E to be epidemiological changes, and categories A, B, and C to  
406 be non-epidemiological changes.

407 A principal component analysis (PCA) supporting the separability of change  
408 categories is detailed in Appendix B.2.

409 *Appendix B.2. PCA analysis of change categories*




Figure B.12: PCA of countries by change category detection rate (i.e. number of changes in each category divided by total changes detected for each country). A) Explained variance ratio by PCA component number; B) PCA factor loadings by change categories.

410 In addition to the dynamical interpretation of constituent time series (Ap-  
411 pendix B), we show the separability of change categories with a principal  
412 component analysis (PCA). The surveillance results of different countries are  
413 quantitatively characterized by a PCA of the relative frequency with which  
414 they detect different categories of changes. The PCA establishes how cate-  
415 gories do or don't represent axes of difference across countries.

416 Based on the curve of explained variance ratio by PCA components (Figure  
417 B.12A), we choose the first three PCA components to examine factor loadings  
418 (Figure B.12B). Each component is dominated by a single category, in PCA  
419 component order: category D (epidemiological change); category B (testing  
420 artifacts); and category E (confounded). Each of these PCA components  
421 is anti-correlated with category A (noise). These relationships among the  
422 different change categories is consistent with our dynamical interpretation.  
423 Figure B.13 shows the frequencies of change categories for those categories  
424 that dominate the factor loadings for all countries in our dataset.




Figure B.13: Change category frequencies by country for categories D, B, and E, chosen according to the dominant categories in the PCA factor loadings.

## 425 Appendix C. Surveillance considerations

426 Below we lay out in basic terms considerations for three components of SARS-  
 427 CoV-2 epidemiological surveillance: population, testing, and their role in  
 428 surveillance metrics. We demonstrate that the testing strategy of random  
 429 testing with the surveillance metric of positivity is the combination that best  
 430 represents SARS-CoV-2 prevalence. Here we use the terminology of SARS-  
 431 CoV-2 to include all asymptomatic and symptomatic infections.

432 Population is composed of people with and without SARS-CoV-2. Of those  
 433 with SARS-CoV-2, some are asymptomatic, some are symptomatic. Of those

434 without SARS-CoV-2, some are non-symptomatic, others have symptoms of  
435 non-COVID-like-illness, and some have COVID-like-illness (CLI) symptoms.

436 Relevant components of testing include eligibility for testing under a given  
437 testing framework, as well as testing rate and capacity. Under random sam-  
438 pling, the general population is eligible for testing; symptomatic testing re-  
439 stricts eligibility to people with CLI symptoms. Testing rate is a measure  
440 of tests conducted per total population, while testing capacity indicates the  
441 proportion of eligible individuals who are actually tested.

442 Detected cases as a surveillance metric is a function of number of tests, the  
443 eligible testing pool, and the total cases within the testing pool. Positivity  
444 is defined as detected cases per tests conducted.

445 Applying these formulations to surveillance metrics, we can see that detected  
446 cases under symptomatic testing is not only a function of number of tests  
447 conducted, but also of the number of individuals exhibiting CLI symptoms.  
448 CLI in turn is a function of non-SARS-CoV-2 CLI and symptomatic SARS-  
449 CoV-2.

450 Positivity under symptomatic testing is normalized for number of tests con-  
451 ducted, measuring not general prevalence in the population, but the portion  
452 of CLI that is symptomatic COVID-19. Metrics derived from symptomatic  
453 testing do not account for asymptomatic SARS-CoV-2 and are confounded  
454 by non-SARS-CoV-2 CLI.

455 As with symptomatic testing, detected cases under random testing are a  
456 function of number of tests. The sampling, however, is taken from the gen-  
457 eral population, and thus positivity under random testing is a metric that  
458 represents prevalence.

459 As tests approach eligible under symptomatic testing, cases detected equals  
460 CLI COVID-19 cases. Note, however, that testing coverage (i.e.  $tests/eligible$ )  
461 is not only influenced by the number of tests processed, but also reporting  
462 rate. Who shows up for testing is a subset of the people who would be eligible  
463 for testing.

464 Assuming capacity to test all eligible individuals and perfect reporting rates,  
465 symptomatic testing would still yield only the number of symptomatic COVID-

466 19 cases. For random testing, testing rate is equivalent to testing coverage,  
467 and case counts depends on testing. The random testing positivity metric  
468 does not depend on testing rate, and captures both symptomatic and asymp-  
469 tomatic COVID. The relationship shown empirically in Section 3.3 wherein  
470 increasingly open testing policies are associated with increasingly effective  
471 epidemiological change monitoring supports the equation-based result that  
472 random testing is more suited to epidemiological surveillance.

Population components:

$$\begin{aligned} Population &= SARS-CoV-2 + Non-SARS-CoV-2 \\ SARS-CoV-2 &= SARS-CoV-2_{asympt} + SARS-CoV-2_{sympt} \\ Non-SARS-CoV-2 &= Non-SARS-CoV-2_{non-sympt} \\ &\quad + Non-SARS-CoV-2_{sympt\_non-CLI} \\ &\quad + Non-SARS-CoV-2_{sympt\_CLI} \end{aligned}$$

Testing components:

$$\begin{aligned} Eligible_{rand} &= Population = SARS-CoV-2 + Non-SARS-CoV-2 \\ Eligible_{sympt} &= CLI = Non-SARS-CoV-2_{sympt\_CLI} + SARS-CoV-2_{sympt} \\ testing\_rate &= Tests/Population \\ testing\_coverage &= Tests/Eligible \end{aligned}$$

Surveillance metrics:

$$\begin{aligned}Cases_{total} &= SARS-CoV-2 \\Cases_{detected} &= Tests * \frac{Cases}{Eligible} \\Positivity &= \frac{Cases_{detected}}{Tests} = \frac{Cases}{Eligible}\end{aligned}$$

Symptomatic testing:

$$\begin{aligned}Cases_{detected\_sympt} &= Tests_{sympt} * \frac{Cases_{sympt}}{CLI} \\Positivity_{sympt} &= \frac{Cases_{sympt}}{CLI}\end{aligned}$$

Random testing:

$$\begin{aligned}Cases_{detected\_rand} &= Tests_{rand} * \frac{Cases_{total}}{Population} \\Positivity_{rand} &= \frac{Cases_{total}}{Population} = Prevalence\end{aligned}$$

#### 473 **Appendix D. Summary statistics**

474 For the purposes of understanding the sensitivity of a given level of testing,  
475 we define the standard error for positivity, as number of positive tests per  
476 total number of tests, we calculate standard error as follows:

$$SE = \sqrt{\frac{p(1-p)}{N} * \frac{N-n}{N-1}}$$

477 Where  $n$  equals total number of tests,  $N$  equals population, and  $p$  equals the  
478 number of positive tests per the total number of tests. The corresponding  
479 margin of error equals one-half the confidence interval, and when calculated  
480 at the 95% confidence level is as follows:

$$ME(95\%) = 1.96 * SE$$

481 Note that this formulation of confidence interval is not reliable when number  
482 of tests is very small, or probabilities are very close to zero or one. Un-  
483 der the condition of true random testing, positivity is a direct measure of  
484 prevalence. At any given prevalence, margin of error can be calculated for  
485 the number of tests administered and the total population. This calcula-  
486 tion is carried out for all LMIC countries in our dataset. Margin of error is  
487 then normalized by the given prevalence rate. Based on these relationships,  
488  $ME(95\%)/Prevalence$  is higher at lower prevalence. In other words, precise  
489 measurement becomes increasingly more difficult as prevalence decreases.

## 490 References

- 491 [1] WHO, COVID-19 Weekly Epidemiological Update, 15 Dec, 2020.
- 492 [2] N. Haider, A. Y. Osman, A. Gadzekpo, G. O. Akipede, D. Asogun,  
493 R. Ansumana, R. J. Lessells, P. Khan, M. M. A. Hamid, D. Yeboah-  
494 Manu, et al., Lockdown measures in response to COVID-19 in nine  
495 sub-Saharan African countries, *BMJ Global Health* 5 (2020) e003319.
- 496 [3] C. A. Petti, C. R. Polage, T. C. Quinn, A. R. Ronald, M. A. Sande, Lab-  
497 oratory medicine in Africa: A barrier to effective health care, *Clinical*  
498 *Infectious Diseases* 42 (2006) 377–382.
- 499 [4] N. K. Ibrahim, Epidemiologic surveillance for controlling COVID-19  
500 pandemic: types, challenges and implications, *Journal of Infection and*  
501 *Public Health* 13 (2020) 1630–1638.
- 502 [5] M. Farahbakhsh, A. Fakhari, H. Azizi, E. Davtalab-Esmaili, Struc-  
503 ture, characteristics and components of COVID-19 surveillance system,  
504 *Journal of Military Medicine* 22 (2020).
- 505 [6] N. A. Alwan, Surveillance is underestimating the burden of the COVID-  
506 19 pandemic, *The Lancet* 396 (2020) e24.
- 507 [7] J. M. Brauner, S. Mindermann, M. Sharma, D. Johnston, J. Salvatier,  
508 T. Gavenčiak, A. B. Stephenson, G. Leech, G. Altman, V. Mikulik,  
509 et al., Inferring the effectiveness of government interventions against  
510 COVID-19, *Science* (2020).



- 511 [8] S. Flaxman, S. Mishra, A. Gandy, H. J. T. Unwin, T. A. Mellan, H. Cou-  
512 pland, C. Whittaker, H. Zhu, T. Berah, J. W. Eaton, et al., Estimating  
513 the effects of non-pharmaceutical interventions on COVID-19 in Europe,  
514 Nature 584 (2020) 257–261.
- 515 [9] S. Hsiang, D. Allen, S. Annan-Phan, K. Bell, I. Bolliger, T. Chong,  
516 H. Druckenmiller, L. Y. Huang, A. Hultgren, E. Krasovich, et al., The  
517 effect of large-scale anti-contagion policies on the COVID-19 pandemic,  
518 Nature 584 (2020) 262–267.
- 519 [10] J. Dehning, J. Zierenberg, F. P. Spitzner, M. Wibral, J. P. Neto,  
520 M. Wilczek, V. Priesemann, Inferring change points in the spread of  
521 COVID-19 reveals the effectiveness of interventions, Science 369 (2020).
- 522 [11] X. Chen, Z. Qiu, Scenario analysis of non-pharmaceutical interventions  
523 on global COVID-19 transmissions, COVID Economics (2020). ArXiv:  
524 2004.04529.
- 525 [12] N. Islam, S. J. Sharp, G. Chowell, S. Shabnam, I. Kawachi, B. Lacey,  
526 J. M. Massaro, R. B. D’Agostino, M. White, Physical distancing inter-  
527 ventions and incidence of coronavirus disease 2019: natural experiment  
528 in 149 countries, BMJ 370 (2020) m2743.
- 529 [13] M. Roser, H. Ritchie, E. Ortiz-Ospina, J. Hasell, Coronavirus pandemic  
530 (COVID-19) (2020).
- 531 [14] T. Hale, T. Boby, N. Angrist, E. Cameron-Blake, L. Hallas, B. Kira,  
532 S. Majumdar, A. Petherick, T. Phillips, H. Tatlow, et al., Oxford  
533 COVID-19 government response tracker (2020).
- 534 [15] Z. Mkhize, Latest confirmed cases of COVID-19 in South Africa (1 nov  
535 2020) (2020).
- 536 [16] National Institute for Communicable Diseases, Weekly testing summary  
537 (2020).
- 538 [17] Statistics South Africa, P0302 - mid-year population estimates, 2020  
539 (2020).
- 540 [18] D. Bradshaw, R. Laubscher, R. Dorrington, P. Groenewald, T. Moultrie,  
541 Report on weekly deaths in South Africa (2020).

- 542 [19] C. Truong, L. Oudre, N. Vayatis, Selective review of offline change  
543 point detection methods, *Signal Processing* 167 (2020) 107299. ArXiv:  
544 1801.00718.
- 545 [20] A. Bershteyn, J. Gerardin, D. Bridenbecker, C. W. Lorton, J. Bloedow,  
546 R. S. Baker, G. Chabot-Couture, Y. Chen, T. Fischle, K. Frey, et al.,  
547 Implementation and applications of EMOD, an individual-based multi-  
548 disease modeling platform, *Pathogens and Disease* 76 (2018).
- 549 [21] J. Qin, C. You, Q. Lin, T. Hu, S. Yu, X.-H. Zhou, Estimation of incu-  
550 bation period distribution of covid-19 using disease onset forward time:  
551 A novel cross-sectional and forward follow-up study, *Science Advances*  
552 6 (2020) eabc1202.
- 553 [22] S. Cousins, Bangladesh’s COVID-19 testing criticised, *The Lancet* 396  
554 (2020) 591.
- 555 [23] N. Pearce, J. P. Vandenbroucke, T. J. VanderWeele, S. Greenland, Ac-  
556 curate statistics on COVID-19 are essential for policy guidance and de-  
557 cisions, *American Journal of Public Health* 110 (2020) 949–951.
- 558 [24] L. H. Hilborne, Z. Wagner, I. Cabrerros, R. H. Brook, Linking statistics  
559 with testing policy to manage COVID-19 in the community, *American*  
560 *Journal of Clinical Pathology* 154 (2020) 142–148.
- 561 [25] N. Haug, L. Geyrhofer, A. Londei, E. Dervic, A. Desvars-Larrive,  
562 V. Loreto, B. Pinior, S. Thurner, P. Klimek, Ranking the effective-  
563 ness of worldwide COVID-19 government interventions, *Nature Human*  
564 *Behaviour* 4 (2020) 1303–1312.
- 565 [26] Y. Liu, C. Morgenstern, J. Kelly, R. Lowe, C. C.-. W. Group,  
566 M. Jit, The impact of non-pharmaceutical interventions on SARS-CoV-  
567 2 transmission across 130 countries and territories, *medRxiv* (2020)  
568 2020.08.11.20172643.
- 569 [27] WHO Regional Office, Africa, COVID-19 in Rwanda: A country’s re-  
570 sponse, WHO — Regional Office for Africa (2020).
- 571 [28] R. Killick, P. Fearnhead, I. A. Eckley, Optimal detection of changepoints  
572 with a linear computational cost, *Journal of the American Statistical*  
573 *Association* 107 (2012) 1590–1598. ArXiv: 1101.1438.

- 574 [29] M. S. Sissoko, K. Sissoko, B. Kamate, Y. Samake, S. Goita, A. Dabo,  
575 M. Yena, N. Dessay, R. Piarroux, O. K. Doumbo, et al., Temporal  
576 dynamic of malaria in a suburban area along the Niger River, *Malaria*  
577 *Journal* 16 (2017) 420.
- 578 [30] B. Ouedraogo, Y. Inoue, A. Kambiré, K. Sallah, S. Dieng, R. Tine,  
579 T. Rouamba, V. Herbreteau, Y. Sawadogo, L. S. L. W. Ouedraogo,  
580 et al., Spatio-temporal dynamic of malaria in Ouagadougou, Burkina  
581 Faso, 2011–2015, *Malaria Journal* 17 (2018) 138.